Items where Author is "Matutes, Estella M."

Article

Ohata, Shinya and Takenaka, Kei and Sugiyama, Daisuke and Sugimoto, Takeshi and Matutes, Estella M. (2022) Bone Marrow Infiltration Is a Distinctive Risk Factor for Rituximab Infusion-Related Reactions in CD20-Positive B-Cell Non-Hodgkin Lymphoma. Advances in Hematology, 2022. pp. 1-7. ISSN 1687-9104

Petrini, Mario and Gaidano, Gianluca and Mengarelli, Andrea and Consoli, Ugo and Santoro, Armando and Liberati, Anna Maria and Ladetto, Marco and Fraticelli, Vincenzo and Guarini, Attilio and Mannina, Donato and Ferrando, Paola and Corradini, Paolo and Musto, Pellegrino and Stelitano, Caterina and Marino, Dario and Camera, Andrea and Murineddu, Marco and Battistini, Roberta and Caparrotti, Giuseppe and Turrini, Mauro and Arcaini, Luca and Santini, Simone and Cerqueti, Manuela and Ferreri, Andres J. M. and Cantore, Nicola and Inzoli, Alessandro and Cardinale, Giovanni and Ronci, Benedetto and La Nasa, Giorgio and Massimi, Stefano and Gaglione, Gianfranco and Barbiero, Valentina and Martelli, Maurizio and Matutes, Estella M. (2022) Safety and Efficacy of Subcutaneous Rituximab in Previously Untreated Patients with CD20+ Diffuse Large B-Cell Lymphoma or Follicular Lymphoma: Results from an Italian Phase IIIb Study. Advances in Hematology, 2022. pp. 1-10. ISSN 1687-9104

Castro, Januario E. and Lengerke-Diaz, Paula A. and Velez Lujan, Juliana and Choi, Michael Y. and Moreno-Cortes, Eider F. and Forero, Jose V. and Garcia-Robledo, Juan Esteban and Jacobs, Chaja and McCarthy, Colin and Heinen, Alaina and Amaya-Chanaga, Carlos I. and Kipps, Thomas J. and Matutes, Estella M. (2022) Ibrutinib plus Obinutuzumab as Frontline Therapy for Chronic Lymphocytic Leukemia Is Associated with a Lower Rate of Infusion-Related Reactions and with Sustained Remissions after Ibrutinib Discontinuation: A Single-Arm, Open-Label, Phase 1b/2 Clinical Trial NCT0231576. Advances in Hematology, 2022. pp. 1-8. ISSN 1687-9104